Company intelligence / Profile preview

T-Balance Therapeutics

Frankfurt am Main, Hessen, Germanyt-balance-therapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Tregalizumab has shown a good safety and tolerability profile that could enable a phase II clinical study in GvHD. The company is currently generating pre-clinical evidence in various T-cell mediated diseases.

Therapeutic areas: Immunology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

tregalizumab

Phase 2

Indications: Graft versus host disease, Autoimmune diseases, Oral lichen planus, Allergic asthma

Partnerships

CD4 Therapeutics GmbH (July 2024 agreement for worldwide rights to develop and commercialize Tregalizumab)

Beyond the preview

Go deeper on T-Balance Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-Balance Therapeutics.

Explore the full profile